APOE genotype affects outcome in a murine model of sepsis: Implications for a new treatment strategy

Anaesthesia and Intensive Care

Volumn 37, Issue 1, 2009, Pages 38-45

  Wang, H ^a   Christensen, D J ^a,b   Vitek, M P ^a,b,c   Sulivan, P M ^a,c   Laskowitz, D T ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Optimal Screening Vehicles Division   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein E; Caecal ligation puncture; Inflammation; Mouse; Sepsis

Indexed keywords

APOLIPOPROTEIN E; COG 1410; COG1410; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; LIGATION; MOUSE; NONHUMAN; PERITONITIS; SEPSIS; SURVIVAL;

EID: 59849111685     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0903700111     Document Type: Article

References (43)

1. Hodgin KE, Moss M. The epidemiology of sepsis. Curr Pharm Des 2008; 14:1833-1839.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
4. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hours in intensiv ecare units in England, Wales, and Northern Ireland. Crit Care Med 2003; 31:2332-2338.
5. Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K. Epidemiology of sepsis in Victoria, Australia. Crit Care Med 2005; 33:71-80.
6. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999; 13:285-297.
7. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994; 45:249-302.
8. Laskowitz DT, Lee DM, Schmechel D, Staats HF. Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 2000; 41:613-620.
9. Curtiss LK, Edgington TS. Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein. J Immunol 1976; 116:1452-1458.
10. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986; 136:3716-3723.
11. Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV et al. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001; 167:74-85.
12. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003; 278:48529-48533.
13. Grocott HP, Newman MF, El-Moalem H, Bainbridge D, Butler A, Laskowitz DT. Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg 2001; 122:622-623.
14. Drabe N, Zund G, Grunenfelder J, Sprenger M, Hoerstrup SP, Bestmann L, Maly FE, Turina M. Genetic predisposition in patients undergoing cardiopulmonary bypass surgery is associated with an increase of inflammatory cytokines. Eur J Cardiothorac Surg 2001; 20:609-613.
15. Grunenfelder J, Comber M, Lachat M, Leskosek B, Turina M, Zund G. Validation of intracoronary shunt flow measurements for off-pump coronary artery bypass operations. Heart Surg Forum 2004; 7:26-30.
16. Laskowitz DT, Fillit H, Yeung N, Toku K, Vitek MP. Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease. Acta Neurol Scand Suppl 2006; 185:15-20.
17. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997; 272:17972-17980.
18. Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 2004; 124:725-733.
19. Entleutner M, Traeger T, Westerholt A, Holzmann B, Stier A, Pfeffer K et al. Impact of interleukin-12, oxidative burst, and iNOS on the survival of murine fecal peritonitis. Int J Colorectal Dis 2005; 21:64-70.
20. Moreno SE, Alves-Filho JC, Alfaya TM, da Silva JS, Ferreira SH, Liew FY. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J Immunol 2006; 177:3218-3224.
21. Novotny AR, Emmanuel K, Ulm K, Bartels H, Siewert J-R, Weighardt H et al. Blood interleukin 12 as preoperative predictor of fatal postoperative sepsis after neoadjuvant radiochemotherapy. Br J Surg 2006; 93:1283-1289.
22. Stohr J, Schindler G, Rothe G, Schmitz G. Enhanced upregulation of the Fc gamma receptor IIIa (CD16a) during in vitro differentiation of ApoE4/4 monocytes. Arterioscler Thromb Vasc Biol 1998; 18:1424-1432.
23. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 2001; 114:107-113.
24. de Bont N, Netea MG, Demacker PN, Verschueren I, Kullberg BJ, van Dijk KW et al. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res 1999; 40:680-685.
25. Roselaar SE, Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res 1998; 39:1740-1743.
26. Van Oosten M, Rensen PC, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJ et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 2001; 276:8820-8824.
27. Rubinsztein DC, Hanlon CS, Irving RM, Goodburn S, Evans DG, Kellar-Wood H et al. Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Mol Cell Probes 1994; 8:519-525.
28. Newman MF, Grocott HP, Mathew JP, White WD, Landolfo K, Reves JG et al. Report of the substudy assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stroke 2001; 32:2874-2881.
29. Moretti EW, Morris RW, Podgoreanu M, Schwinn DA, Newman MF, Bennett E et al. APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit Care Med 2005; 33:2521-2526.
30. Ely EW, Girard TD, Shintani AK, Jackson JC, Gordon SM, Thomason JWW et al. Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients. Crit Care Med 2007; 35:112-117.
31. Murch O, Collin M, Hinds CJ, Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007; 33:13-24.
32. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007; 33:25-35.
33. Cockerill GW, McDonald MC, Mota-Filipe H, Cuzzocrea S, Miller NE, Thiemermann C. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J 2001; 15:1941-1952.
34. Hubsch AP, Casas AT, Doran JE. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med 1995; 126:548-558.
35. Rensen PC, Oosten M, Bilt E, Eck M, Kuiper J, Berkel TJ. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest 1997; 99:2438-2445.
36. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990; 58:2375-2382.
37. Y uhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7:853-857.
38. Gupta H, Dai L, Datta G, Garber DW, Grenett H, Li Y et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005; 97:236-243.
39. Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging 2007; Epub ahead of print:n/a.
40. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI et al. Cecal ligation and puncture. Shock 2005; 24 (Suppl 1):52-57.
41. Gao J, Wang H, Sheng H, Lynch JR, Warner DS, Durham L et al. A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit Care 2006; 4:25-31.
42. Laskowitz DT, McKenna SE, Song P, Wang H, Durham L, Yeung N et al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma 2007; 24:1093-1107.
43. Misra UK, Adlakha CL, Gawdi G, McMillian MK, Pizzo SV, Laskowitz DT. Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages. J Leukoc Biol 2001; 70:677-683.